Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001193125-25-245087
Filing Date
2025-10-21
Accepted
2025-10-21 16:05:06
Documents
2
Period of Report
2025-10-14

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1589
2 EX-24.1 atos-ex24_1.htm EX-24.1 10045
  Complete submission text file 0001193125-25-245087.txt   13165
Mailing Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125
Business Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125 206.588.0256
ATOSSA THERAPEUTICS, INC. (Issuer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125
Business Address
Daniel Mark James (Reporting) CIK: 0002092593 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-35610 | Film No.: 251407070